These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 1698319)

  • 1. T cell depletion with anti-CD5 immunotoxin in histocompatible bone marrow transplantation. The correlation between residual CD5 negative T cells and subsequent graft-versus-host disease.
    Filipovich AH; Vallera D; McGlave P; Polich D; Gajl-Peczalska K; Haake R; Lasky L; Blazar B; Ramsay NK; Kersey J
    Transplantation; 1990 Sep; 50(3):410-5. PubMed ID: 1698319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Graft-versus-host disease prevention in allogeneic bone marrow transplantation from histocompatible siblings. A pilot study using immunotoxins for T cell depletion of donor bone marrow.
    Filipovich AH; Vallera DA; Youle RJ; Haake R; Blazar BR; Arthur D; Neville DM; Ramsay NK; McGlave P; Kersey JH
    Transplantation; 1987 Jul; 44(1):62-9. PubMed ID: 3299923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific ex-vivo depletion of human bone marrow T lymphocytes by an anti-pan-T cell (CD5) ricin A-chain immunotoxin.
    Siena S; Villa S; Bonadonna G; Bregni M; Gianni AM
    Transplantation; 1987 Mar; 43(3):421-6. PubMed ID: 3103275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors.
    Koehler M; Hurwitz CA; Krance RA; Coustan-Smith E; Williams LL; Santana V; Ribeiro RC; Brenner MK; Heslop HE
    Bone Marrow Transplant; 1994 May; 13(5):571-5. PubMed ID: 7519937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of graft-versus-host disease with anti-CD5 ricin A chain immunotoxin after CD3-depleted HLA-nonidentical marrow transplantation in pediatric leukemia patients.
    Przepiorka D; Chan KW; Champlin RE; Culbert SJ; Petropoulos D; Ippoliti C; Khouri I; Huh YO; Vreisendorp H; Deisseroth AB
    Bone Marrow Transplant; 1995 Dec; 16(6):737-41. PubMed ID: 8750262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-CD2 (T, p50) intact ricin immunotoxins for GVHD-prophylaxis in allogeneic bone marrow transplantation.
    Uckun FM; Azemove SM; Myers DE; Vallera DA
    Leuk Res; 1986; 10(2):145-53. PubMed ID: 3512922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination graft-versus-host disease prophylaxis using immunotoxin (anti-CD5-RTA [Xomazyme-CD5]) plus methotrexate and cyclosporine or prednisone after unrelated donor marrow transplantation.
    Weisdorf D; Filipovich A; McGlave P; Ramsay N; Kersey J; Miller W; Blazar B
    Bone Marrow Transplant; 1993 Nov; 12(5):531-6. PubMed ID: 8298565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Depletion of bone marrow T-lymphocytes with an anti-CD5 monoclonal immunotoxin (ST-1 immunotoxin): effective prophylaxis for graft-versus-host disease.
    Antin JH; Bierer BE; Smith BR; Guinan EC; Provost MM; Ferrara J; Macklis RM; Tarbell NJ; Blythman H; Bouloux C
    Prog Clin Biol Res; 1990; 333():207-15. PubMed ID: 1689852
    [No Abstract]   [Full Text] [Related]  

  • 9. Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies.
    Antin JH; Bierer BE; Smith BR; Ferrara J; Guinan EC; Sieff C; Golan DE; Macklis RM; Tarbell NJ; Lynch E
    Blood; 1991 Oct; 78(8):2139-49. PubMed ID: 1717080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of treating marrow with a CD3-specific immunotoxin for prevention of acute graft-versus-host disease.
    Martin PJ; Hansen JA; Torok-Storb B; Moretti L; Press O; Storb R; Thomas ED; Weiden PL; Vitetta ES
    Bone Marrow Transplant; 1988 Sep; 3(5):437-44. PubMed ID: 2973360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapy for ongoing graft-versus-host disease induced across the major or minor histocompatibility barrier in mice with anti-CD3F(ab')2-ricin toxin A chain immunotoxin.
    Vallera DA; Taylor PA; Panoskaltsis-Mortari A; Blazar BR
    Blood; 1995 Dec; 86(11):4367-75. PubMed ID: 7492798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation.
    Martin PJ; Nelson BJ; Appelbaum FR; Anasetti C; Deeg HJ; Hansen JA; McDonald GB; Nash RA; Sullivan KM; Witherspoon RP; Scannon PJ; Friedmann N; Storb R
    Blood; 1996 Aug; 88(3):824-30. PubMed ID: 8704237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro analysis of donor bone marrow following monoclonal antibody treatment for the prevention of acute graft versus host disease.
    Kohler PC; Erickson C; Finlay JL; Trigg ME; Edwards B; Hong R; Hank JA; Billing R; Bozdech M; Sondel PM
    Cancer Res; 1986 Oct; 46(10):5413-8. PubMed ID: 3530439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Donor bone marrow treatment with T101 Fab fragment-ricin A-chain immunotoxin prevents graft-versus-host disease.
    Laurent G; Maraninchi D; Gluckman E; Vernant JP; Derocq JM; Gaspard MH; Rio B; Michalet M; Reiffers J; Dreyfus F
    Bone Marrow Transplant; 1989 Jul; 4(4):367-71. PubMed ID: 2789084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of anti-CD5 ricin A chain immunoconjugate for prevention of acute graft-vs.-host disease after HLA-identical marrow transplantation.
    Przepiorka D; LeMaistre CF; Huh YO; Luna M; Saria EA; Brown CT; Champlin RE
    Ther Immunol; 1994 Apr; 1(2):77-82. PubMed ID: 7584486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reconstitution of T-cell function after CD6-depleted allogeneic bone marrow transplantation.
    Soiffer RJ; Bosserman L; Murray C; Cochran K; Daley J; Ritz J
    Blood; 1990 May; 75(10):2076-84. PubMed ID: 1970938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of graft-versus-host disease by selective depletion of CD6-positive T lymphocytes from donor bone marrow.
    Soiffer RJ; Murray C; Mauch P; Anderson KC; Freedman AS; Rabinowe SN; Takvorian T; Robertson MJ; Spector N; Gonin R
    J Clin Oncol; 1992 Jul; 10(7):1191-200. PubMed ID: 1607923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of murine graft-versus-host disease and bone marrow alloengraftment across the major histocompatibility barrier after donor graft preincubation with anti-LFA1 immunotoxin.
    Blazar BR; Carroll SF; Vallera DA
    Blood; 1991 Dec; 78(11):3093-102. PubMed ID: 1954395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of graft-versus-host reactivity after small bowel transplantation: ex vivo treatment of intestinal allografts with an anti-T cell immunotoxin.
    Clark CL; Smith GJ; Crane PW; Price BA; Lear PA; Fabre JW; Wood RF
    Clin Exp Immunol; 1992 May; 88(2):220-5. PubMed ID: 1373997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.